Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 94-101 , Summer 2008

Paracrine Effects of Cell Transplantation: Strategies to Augment the Efficacy of Cell Therapies

  • Andrew S. Cheng, BSc
    • ,
  • Terrence M. Yau, MD, MSc

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Terrence M. Yau, MD, MSc, Division of Cardiovascular Surgery, Toronto General Hospital, University Health Network, 4N-470, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada

References 

  1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  2. Roell W, Lu ZJ, Bloch W, et al. Cellular cardiomyoplasty improves survival after myocardial injury. Circulation. 2002;105:2435–2441
  3. Pouzet B, Vilquin JT, Hagege AA, et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg. 2001;71:844–851
  4. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2001;103:1920–1927
  5. Pouzet B, Vilquin JT, Hagege AA, et al. Intramyocardial transplantation of autologus myoblasts: can tissue processing be optimized?. Circulation. 2000;102(suppl 3):210–215
  6. Li RK, Weisel RD, Mickle DAG, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg. 2000;119:62–68
  7. Sakai T, Li RK, Weisel RD, et al. Autologous heart cell transplantation improves cardiac function after myocardial injury. Ann Thorac Surg. 1999;68:2074–2080
  8. Li RK, Jia ZQ, Weisel RD, et al. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol. 1999;31:513–522
  9. Atkins BZ, Hueman MT, Meuchel J, et al. Cellular cardiomyoplasty improves diastolic properties of injured heart. J Surg Res. 1999;85:234–242
  10. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929–933
  11. Scorsin M, Hagege A, Marotte F, et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium?. Circulation. 1997;96(suppl 2):188–193
  12. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg. 1996;62:654–660
  13. Kim EJ, Li RK, Weisel RD, et al. Angiogenesis by endothelial cell transplantation. J Thorac Cardiovasc Surg. 2001;122:963–971
  14. Scorsin M, Hagege A, Vilquin J, et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg. 2000;119:1169–1175
  15. Hutcheson KA, Atkins BZ, Hueman MT, et al. Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. Cell Transplant. 2000;9:359–368
  16. Sakai T, Li RK, Weisel RD, et al. Fetal cell transplantation: a comparison of three cell types. J Thorac Cardiovasc Surg. 1999;118:715–725
  17. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100(suppl 2):247–256
  18. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430–436
  19. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705
  20. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726–1732
  21. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001;104:1046–1052
  22. Tomita S, Mickle DAG, Weisel RD, et al. Improved heart function with myogenesis and angiogenesis following autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg. 2002;123:1132–1140
  23. Galli D, Innocenzi A, Staszewsky L, et al. Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25:692–697
  24. Yau TM, Tomita S, Weisel RD, et al. Beneficial effect of autologous cell transplantation on infarcted heart function: direct comparison between bone marrow stromal cells and heart cells. Ann Thorac Surg. 2003;75:169–176
  25. Tang YL, Zhao Q, Qin X, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80:229–236
  26. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368
  27. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543–1549
  28. Tang YL, Qian K, Zhang YC, et al. Mobilizing of hematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1alpha (SDF-1alpha) treatment. Regul Pept. 2005;125:1–8
  29. Fedak PW, Szmitko PE, Weisel RD, et al. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J Thorac Cardiovasc Surg. 2005;130:1430–1439
  30. Suzuki K, Murtuza B, Smolenski RT, et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor expressing skeletal myoblasts. Circulation. 2001;104(suppl 1):207–212
  31. Yau TM, Fung K, Weisel RD, et al. Enhanced myocardial angiogenesis by gene transfer with transplanted cells. Circulation. 2001;104:I218–I222
  32. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661–669
  33. Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA. 2007;104:1643–1648
  34. Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25:2363–2370
  35. Ohnishi S, Sumiyoshi H, Kitamura S, et al. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett. 2007;581:3961–3966
  36. Ohnishi S, Yanagawa B, Tanaka K, et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol. 2007;42:88–97
  37. Xu M, Uemura R, Dai Y, et al. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol. 2007;42:441–448
  38. Tse HF, Siu CW, Zhu SG, et al. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischemic myocardium. Eur J Heart Fail. 2007;9:747–753
  39. Zeng L, Hu Q, Wang X, et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation. 2007;115:1866–1875
  40. Iso Y, Spees JL, Serrano C, et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun. 2007;354:700–706
  41. Yau TM, Kim C, Li G, et al. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation. 2005;112:8
  42. Yau TM, Li G, Zhang Y, et al. Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy. Ann Thorac Surg. 2005;79:2056–2064
  43. Li W, Ma N, Ong LL, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells. 2007;25:2118–2127
  44. Niagara MI, Haider H, Jiang S, et al. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007;100:545–555
  45. Uemura R, Xu M, Ahmad N, et al. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res. 2006;98:1414–1421
  46. Zhang M, Mal N, Kiedrowski M, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007;21:3197–3207
  47. Formigli L, Perna AM, Meacci E, et al. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodeling. J Cell Mol Med. 2007;11:1087–1100
  48. Kofidis T, de Bruin JL, Yamane T, et al. Stimulation of paracrine pathways with growth factors enhances embryonic stem cell engraftment and host-specific differentiation in the heart after ischemic myocardial injury. Circulation. 2005;111:2486–2493
  49. Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006;14:840–850
  50. Tang YL, Zhao Q, Zhang YC, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2004;117:3–10
  51. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109:1292–1298
  52. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005;118:3759–3768
  53. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2004;104:3581–3587
  54. Kahn J, Byk T, Jansson-Sjostrand L, et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood. 2004;103:2942–2949
  55. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848
  56. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322–1328
  57. Jo DY, Hwang JH, Kim JM, et al. Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of hematopoietic progenitors. Br J Hematol. 2003;121:649–652
  58. Kucia M, Ratajczak J, Reca R, et al. Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. Blood Cells Mol Dis. 2004;32:52–57
  59. Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300–3305
  60. Cimini M, Fazel S, Zhuo S, et al. c-kit dysfunction impairs myocardial healing after infarction. Circulation. 2007;116:I77–I82
  61. Fazel S, Chen L, Weisel RD, et al. Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg. 2005;130:1310
  62. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763–776
  63. Urbanek K, Quaini F, Tasca G, et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:10440–10445
  64. Linke A, Muller P, Nurzynska D, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA. 2005;102:8966–8971
  65. Wang M, Crisostomo PR, Herring C, et al. Human progenitor cells from bone marrow or adipose tissue produce VEGF (HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism). Am J Physiol Regul Integr Comp Physiol. 2006;291:R880–R884
  66. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Regul Integr Comp Physiol. 2006;290:203
  67. Xu X, Xu Z, Xu Y, et al. Selective down-regulation of extracellular matrix gene expression by bone marrow derived stem cell transplantation into infarcted myocardium. Circ J. 2005;69:1275–1283
  68. Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation. 2005;112:214–223
  69. Kim C, Li RK, Li G, et al. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg. 2007;83:640–646
  70. Yau TM, Kim C, Li G, et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg. 2007;83:1110–1120
  71. Yau TM, Kim C, Ng D, et al. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg. 2005;80:1779–1786
  72. Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2005;25:1168–1173
  73. Yang J, Zhou W, Zheng W, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology. 2007;107:17–29
  74. Jiang S, Haider H, Idris NM, et al. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res. 2006;99:776–784
  75. Shi Y, Baker JE, Zhang C, et al. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heart shock protein 90 association and serine phosphorylation. Circ Res. 2002;91:300–306

 TMY is supported by the Angelo and Lorenza DeGasperis Chair in Cardiovascular Surgery Research.

PII: S1043-0679(08)00069-5

doi: 10.1053/j.semtcvs.2008.04.003

Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 94-101 , Summer 2008

Article Tools

* Image Usage & Resolution